SynOx Therapeutics

SynOx Therapeutics Adds Gilde Healthcare as New Investor, Increasing Total Series B Raise to $92 Million. Doses First Patients in Phase 3 Trial in TGCT

July is Sarcoma Awareness Month. Sarcoma is a group of cancers that begin in the bones and soft tissues. Tenosynovial giant cell tumor (TGCT) is a non-malignant, debilitating disease that also invades soft tissues and causes joint damage, swelling, pain, and reduced function. By sharing knowledge, resources and best practices we can make a difference for patients. Increased collaboration among medical professionals, researchers, patient advocacy groups and other stakeholders leads to better and earlier diagnoses, improved therapies, and better outcomes for those battling this rare disease. At SynOx we are dedicated to supporting this vision.    #SarcomaAwareness #RareDisease #TGCT  

This morning, SynOx Therapeutics announced that it has entered into a $35m loan facility with Hercules Capital. This funding, in addition to the $75 million Series B fundraise which closed last week, will give SynOx the flexibility to fund additional work in #TGCT. Raymond Barlow Barlow, Chief Executive Officer of SynOx Therapeutics, said: “This funding will provide SynOx with additional capital to fulfil its mission of establishing emactuzumab as a best-in-class drug, to address significant unmet medical needs and greatly improve the quality of life for as many patients as possible. We are grateful for the support from Hercules, which together with the $75m we raised recently in our Series B round, puts SynOx on a strong financial footing.” Read more about this debt financing in the full press release which is linked in the comments below! https://lnkd.in/e_BZYMG2 #financing 

Today, SynOx Therapeutics announces it has secured up to $35 million debt financing with Hercules Capital.   This follows the recent close of our Series B financing where we raised $75 million to accelerate the development of #emactuzumab for the treatment of #TGCT, a debilitating tumour of the joints. This loan facility will strengthen @SynOx's balance sheet and provides us with flexibility to fund additional clinical and commercial work in #TGCT.   Additionally, this gives SynOx the potential to explore this CSF-1(R) inhibiting monoclonal antibody (mAb) in other CSF-1 driven and macrophage-mediated diseases.   Read more about this debt financing in the full press release which is also linked in the comments below!  

https://lnkd.in/eaN-FvQr #synoxtherapeutics #tgct #financing #csf1 Raymond BarlowBroes NaeyeSarah Clare Sander Veltkamp Ton Logtenberg

https://lnkd.in/eaN-FvQr

https://lnkd.in/eaN-FvQr

https://lnkd.in/eaN-FvQr

We are excited to announce the successful close of our $75 million Series B financing! This financing was co-led by Forbion and HealthCap, as well as our new investor Bioqube Ventures, who we are delighted to welcome.   The funding will be used to generate registrational Phase 3 clinical and CMC data for #emactuzumab, our potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of Tenosynovial Giant Cell Tumour (TGCT).   We are also very proud to welcome both Carlo Incerti, M.D., and Jon Edwards, PhD, to our Board of Directors. Their broad experience and knowledge will be instrumental as we accelerate the development of emactuzumab.   To learn more about the financing and our late stage clinical trial, see the full press release linked in the comments below   #biotech #financing #investment #tgct #BIC #emactuzumab